Andrew Bayliffe

Andrew Bayliffe is chief scientific officer at Marengo Therapeutics and a venture partner at ATP.
With more than 20 years of leadership experience in the biopharmaceutical industry, he possesses expertise in the discovery and development of both small molecule and antibody therapeutics across a broad range of diseases areas.
Most recently, at GlaxoSmithKline (GSK), he served as head of the Fibrosis and Lung Injury Discovery unit at GSK’s R&D headquarters in Stevenage, UK, and held senior roles in antibody discovery and development in the US and UK.
Andrew is an honorary professor at the Wolfson Institute of Experimental Medicine at Queens College in Belfast.
He completed his undergraduate and PhD studies in pharmacology, physiology, and molecular biology at Manchester University and Leeds University in the UK.